by Madaline Spencer | Feb 11, 2025
Arturo Molina, MD, Protagonist Therapeutics, discusses results from the phase 2 REVIVE clinical trial testing rusfertide in patients with polycythemia vera (PV). PV is a myeloproliferative disorder characterized by an elevated absolute red blood cell...
by Madaline Spencer | Feb 10, 2025
Michael Denne, PharmD, Vice President of US Medical Affairs at Takeda, discusses results from clinical trials evaluating rADAMTS13 in patients with congenital thrombotic thrombocytopenic purpura (cTTP). cTTP is characterized by profound peripheral...
by Madaline Spencer | Feb 7, 2025
Ken Gorson, MD, Tufts University School of Medicine, discusses topline results from real-world evidence study evaluating ANX005 in patients with Guillain-Barré syndrome (GBS). GBS is an acute, rapidly progressive neurological disease consisting of a...
by Madaline Spencer | Feb 6, 2025
Paula Ragan, President and Chief Executive Officer of X4 Pharmaceuticals, discusses the pathway of approval under the European Medicines Agency (EMA) for mavorixafor for patients with WHIM syndrome. WHIM syndrome is an acronym for a rare immunodeficiency...
by Madaline Spencer | Feb 5, 2025
Emma Searle, PhD, The Christie NHS Foundation Trust and University of Manchester, discusses bleximenib in combination with chemotherapy to treat patients with acute myeloid leukemia (AML). AML is a group of neoplasms arising from precursor cells...
